Cargando…

Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4

Direct-acting antiviral drugs to cure infections with Hepatitis C virus (HCV) achieve a sustained virological response (SVR) in more than 90% of adult patients. At present, clinical trials are ongoing and real-life data are still limited in children. Herein, we report two cases of pediatric patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marascio, Nadia, Mazzitelli, Maria, Pavia, Grazia, Giancotti, Aida, Barreca, Giorgio Settimo, Costa, Chiara, Pisani, Vincenzo, Greco, Giuseppe, Serapide, Francesca, Trecarichi, Enrico Maria, Casalinuovo, Francesco, Liberto, Maria Carla, Matera, Giovanni, Torti, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562692/ https://www.ncbi.nlm.nih.gov/pubmed/31060315 http://dx.doi.org/10.3390/cells8050416

Ejemplares similares

Phylogenetic and Molecular Analyses of More Prevalent HCV1b Subtype in the Calabria Region, Southern Italy
por: Marascio, Nadia, et al.
Publicado: (2021)

Virological Mechanisms in the Coinfection between HIV and HCV
por: Liberto, Maria Carla, et al.
Publicado: (2015)

Clinical outcomes of patients treated with intravenous zanamivir for severe influenza A(H1N1)pdm09 infection: a case report series
por: Torti, Carlo, et al.
Publicado: (2019)

Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy)
por: Scaglione, Vincenzo, et al.
Publicado: (2020)

Severe myocarditis due to influenza A(H1N1)pdm09 viral infection in a young woman successfully treated with intravenous zanamivir: A case report
por: Mazzitelli, Maria, et al.
Publicado: (2019)

Evaluation of IL-35, as a Possible Biomarker for Follow-Up after Therapy, in Chronic Human Schistosoma Infection
por: Marascio, Nadia, et al.
Publicado: (2023)

Role of the T2Dx magnetic resonance assay in patients with suspected bloodstream infection: a single-centre real-world experience
por: Quirino, Angela, et al.
Publicado: (2022)

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection
por: Marascio, Nadia, et al.
Publicado: (2019)

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2017)

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection
por: Alkaaby, Ban Adil, et al.
Publicado: (2018)

Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals
por: Strazzulla, Alessio, et al.
Publicado: (2014)

Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients
por: Marascio, Nadia, et al.
Publicado: (2016)

Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients
por: Mazzitelli, Maria, et al.
Publicado: (2018)

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
por: Berenguer, Juan, et al.
Publicado: (2019)

Microbiological and Clinical Findings of SARS-CoV-2 Infection after 2 Years of Pandemic: From Lung to Gut Microbiota
por: Russo, Alessandro, et al.
Publicado: (2022)

The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview
por: Marascio, Nadia, et al.
Publicado: (2022)

Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection
por: Havens, Joshua P., et al.
Publicado: (2020)

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
por: Wang, Gary P., et al.
Publicado: (2018)

Challenging clinical cases in HCV infection
por: Strazzulla, Alessio, et al.
Publicado: (2014)

Utility of Molecular Identification and Quantitation of Bartonella Species with Species-Specific Real-Time PCR for Monitoring Treatment Response: A Case Series
por: Mazzitelli, Maria, et al.
Publicado: (2018)

Eleven-Year Distribution Pattern of Hepatitis C Virus in Southern Italy
por: Marascio, Nadia, et al.
Publicado: (2012)

Update on different aspects of HCV variability: focus on NS5B polymerase
por: Marascio, Nadia, et al.
Publicado: (2014)

In vitro Activity of Cefiderocol Against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: a Single Center Experience
por: Quirino, Angela, et al.
Publicado: (2023)

Prevalence of Antibiotic Resistance Over Time in a Third-Level University Hospital
por: Scaglione, Vincenzo, et al.
Publicado: (2022)

Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
por: Ogbuagu, Onyema, et al.
Publicado: (2018)

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
por: Lee, Soon Kyu, et al.
Publicado: (2022)

Spontaneous and Severe Haematomas in Patients with COVID-19 on Low- Molecular-Weight Heparin for Paroxysmal Atrial Fibrillation
por: Mazzitelli, Maria, et al.
Publicado: (2020)

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
por: Do, Albert, et al.
Publicado: (2015)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
por: Premji, Resmi, et al.
Publicado: (2015)

Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir
por: Shenk, Mary Elizabeth Reed, et al.
Publicado: (2018)

Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV–HCV Coinfection
por: Doyle, Mary-Anne, et al.
Publicado: (2019)

Real-world Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1
por: Ruane, Peter, et al.
Publicado: (2017)

Real World Experience of Sofosbuvir/Ledipasvir Therapy in HIV Patients Co-infected with HCV: A Retrospective Study
por: Al Obaidi, Mohanad, et al.
Publicado: (2017)

Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report
por: Alcazer, Vincent, et al.
Publicado: (2018)

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)

The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV)
por: Golabi, Pegah, et al.
Publicado: (2016)

Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice
por: Marascio, Nadia, et al.
Publicado: (2022)

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient
por: Thalhammer, Julian, et al.
Publicado: (2021)

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cj9hse0ql4blfrqaf9mk67cav5